Molecular Cellular Biology Laboratory

-A +A

RESEARCH AREAS

  • Development of anticancer drug molecules
  • Molecular mechanisms of carcinogenesis
  • Apoptosis
  • The role of apoptosis and oxidative stress in cardiovascular diseases
  • Molecular pathways invovled in the development of aneurysms
  • Tissue Engineering
  • In vivo – in vitro Toxicology
  • Evaluation of bioactivity and biocompatibility of pharmaceuticals, biomaterials, and medical devices
  • Development of in vitro methods for animal alternatives
  • Nanotoxicology
  • Risk assessment

Molecular Cellular Biology Laboratory (MCBL) is a well established laboratory with its technological infrastructure and expert researchers leading advanced and innovative R & D activities. MCBL provides  high-quality solutions and pursues projects for both the industry and public organizations  to meet national needs with its know-how and technological background.

One of the research interests of the MCB staff is development of novel synthetic drug molecules for anticancer therapy. Among the anticancer drugs, metal based agents act through apoptosis of cancer cells via induction of DNA damage; and appear as promising compounds. MCBL has recently been focusing on the characterization of Palladium based metal complexes and their mechanism of action. Molecules that grant premise for in vivo studies are tested on animal models for their antitumor acitivity and toxicological properties in comparison to commertial FDA approved counterparts.

MCBL also directs and takes part in TUBITAK 1003 projects regarding tissue engineering involving regeneration of cartilage and cardiac tissues using mesencymal stem cells on biodegradable 3D scaffolds.   

MCBL also participated in the EU framework programme projects, and had previously investigated the molecular and genetic factors leading to formation of aortic aneurysms within the scope of the project entitled “Fighting Aneurysmal Disease”. In this project, the first biobank for blood, serum, DNA/RNA, tissue and cell banks of aneurysm patients have been formed and characterized. Gene expression changes during aneurysm development, apoptotic mechanisms leading to loss of smooth muscle cells in the wall of the  aorta, and the damage induced by increased oxidative stress in these patients were also examined.

MCB lab is leading projects and offering industrial services including evaluation of bioactivity, lab scale production, and preclinical studies of pharmaceuticals and testing biocompatibility of medical devices.